Eli Lilly Q2 growth focus: Mounjaro and Zepbound seen as drivers for up to 98% of quarterly increase
Eli Lilly and Company is set for a tight earnings test on Wednesday. Initial projections indicate that Mounjaro and Zepbound will account for about 98% of the revenue increase in the second quarter.
